- New

MELANOV MR (generic name: Gliclazide) is a medication used for controlling blood
Description:
1. Indications and Dosage
(a) As a conventional tablet: Initially, take 40-80 mg daily; adjust as needed until adequate control is achieved. The maximum daily dose is 320 mg, given in 2 divided doses.
(b) As a modified-release tablet: Start with 30 mg daily; increase by 30 mg increments at intervals of at least 1 month (or after 2 weeks if no decrease in blood glucose is observed). The maximum daily dose is 120 mg. The 80 mg conventional tablet is comparable to the 30 mg modified-release tablet, and switching can be done with close blood glucose monitoring.
(c) Renal impairment: Severe renal impairment is contraindicated.
(d) Hepatic impairment: Severe hepatic impairment is contraindicated.
(e) Administration: Take with food.
2. Contraindications
(a) Hypersensitivity to gliclazide, other sulfonylureas, or sulfonamides.
(b) Type 1 diabetes mellitus, diabetic coma, and pre-coma, as well as diabetic ketoacidosis.
(c) Severe hepatic or renal impairment.
(d) Pregnancy and lactation.
(e) Concomitant use with miconazole.
3. Special Precautions
(a) Monitor for signs of hypoglycemia.
(b) Use with caution in patients with risk factors for hypoglycemia, G6PD deficiency, porphyria, stress-related states, mild to moderate hepatic or renal impairment, and in the elderly.
(c) Rarely, serious skin and hypersensitivity reactions may occur.